Senores Pharmaceuticals (NSE:SENORES) Construction In Progress: ₹175 Mil (As of Mar. 2026)


NSE:SENORES Senores Pharmaceuticals Ltd NSE:SENORES
18 GF Score
Price ₹1,313.10
! 7 Warning Signs
View Full Analysis

What is Senores Pharmaceuticals Construction In Progress?

Senores Pharmaceuticals NSE:SENORES -1.26% 18 Construction In Progress is ₹175 Mil as of Mar. 2026. GuruFocus rates NSE:SENORES with a GF Score™ of 18/100. The stock has 7 warning signs investors should review.

Senores Pharmaceuticals's quarterly construction in progress declined from Sep. 2025 (₹160 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹175 Mil).

Senores Pharmaceuticals's annual construction in progress increased from Mar. 2024 (₹208 Mil) to Mar. 2025 (₹516 Mil) but then declined from Mar. 2025 (₹516 Mil) to Mar. 2026 (₹175 Mil).

Senores Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Senores Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senores Pharmaceuticals Construction In Progress Chart

Senores Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
3.45 89.89 208.10 515.50 174.60

Senores Pharmaceuticals Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 515.50 0.00 160.10 0.00 174.60
NSE:SENORES
18GF Score
Senores Pharmaceuticals Ltd NSE:SENORES
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senores Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹175 Mil mean?
Senores Pharmaceuticals (NSE:SENORES) has a Construction In Progress of ₹175 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Senores Pharmaceuticals and its competitors.
Is Senores Pharmaceuticals' Construction In Progress too high?
Senores Pharmaceuticals' current Construction In Progress is ₹175 Mil. Overall, Senores Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' Construction In Progress compare to LLY and JNJ?
Senores Pharmaceuticals' Construction In Progress of ₹175 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Senores Pharmaceuticals and its competitors. Senores Pharmaceuticals's current Construction In Progress is ₹175 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current Construction In Progress of ₹175 Mil. The current Construction In Progress is ₹175 Mil. Senores Pharmaceuticals' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current Construction In Progress is ₹175 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senores Pharmaceuticals Business Description

Other Exchanges 544319:India
Address Ambali Bopal Road, 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ahmedabad, GJ, IND, 380054
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
18GF Score

Get the complete analysis for NSE:SENORES

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,313.10
Price